PaverGuide has developed a product called PaverGuide™, an injection-molded, recycled plastic, modular system designed to replace stone as a road base and reservoir below permeable paving. The reservoir allows for infiltration, or beneficial harvesting of storm water.

PaverGuide™ is a structural base for paving systems and exceeds H-20 loading. PaverGuide™ is installed faster and cheaper than the stone it replaces, and at 90 percent void, it provides a large rainwater reservoir and expansive infiltration surface.

Belloso Motor Company has developed a Dual-Engine Technology System that provides significantly improved fuel economy without sacrificing performance or requiring expensive and complex hybrid technology.

Xcision Medical Systems is a medical technology company developing advanced stereotactic radiotherapy solutions with the potential to dramatically raise the quality of treatments and improve the lives of patients and their loved ones. The company’s solutions are designed to extend the benefits of radiation oncology to more patients and enable noninvasive treatments that allow patients to return to living fuller lives more quickly and less painfully after receiving a cancer diagnosis.

Xcision’s initial focus is on breast cancer, using stereotactic partial breast irradiation to treat patients eligible for breast-conserving therapy. The company’s first product, GammaPod™, is a new, stereotactic radiotherapy system optimized for the treatment of breast cancer in 1-5 sessions.

Werbie’s mission is to build solutions for women with diabetes. The company focuses on women because women have unique physical and emotional needs that the company’s team of medical and tech experts is uniquely qualified to address. Werbie’s first product, the GlucoseMama Kit for gestational diabetes mellitus (GDM), is a one-box solution containing the necessary hardware and software for patients to self-manage GDM. In the future, Werbie will also create customized kits for type 2 and type 1 diabetes in non-pregnant women. The company’s aim is to help all women self-manage diabetes, with a focus on psychosocial support, nutrition guidance, and assistance with medication and insulin dosing.

Solar Tech Inc. is selling SolarTechPrints solar panels to roofers and related solar energy contractors to install on their clients’ homes and businesses

SolarTechPrints (STPs) are lightweight, flexible solar panels that can be rolled for shipping purposes and can be easily applied by contractors and customers alike. There are seven layers required for STPs to work: a base paper/foil layer, a layer of zinc oxide nanocrystals, a layer of silver nanopowder, a layer of nickel oxide nanocrystals, a layer of tin perovskites, a layer of silver nanowires, and a final protective layer of a clear UV-resistant lacquer. From the manufacturer’s standpoint, this product is easily produced through the use of a specialized printer. Its inorganic compounds are also beneficial in that they will heighten the product’s lasting power.

STPs are based on a prototype with a licensed patent of a solar spray produced by Townsend.

A&G is focused on the identification of biomarkers involved in the development of cancer cells and using such biomarkers as targets, developing theranostic (diagnostic and therapeutic combination) products useful in the diagnosis, treatment and monitoring of cancer. The company is comprised of two divisions, an R&D division focused on theranostic products, and the Precision Antibody division, recognized worldwide as a provider of high-quality, customized antibodies to pharmaceutical and biotech companies, as well as federal laboratories.

A&G has grown from an incubator company with four employees to a 12,000 sq.-ft. facility with 30 employees, of whom >50 percent are Maryland graduates. A&G’s financing is a mix of equity funding and profits from Precision Antibody. Non-dilutive funding has been obtained from NIH and Avon Foundation grants. The MIPS funding of studies at the University of Maryland have been important in the company’s goal of developing diagnostic kits for its theranostic portfolio.

A&G’s lead products in development, based on a unique biomarker called GP88 (progranulin), target both lung and breast cancer, as well as several other cancers. GP88, a glycoprotein, is produced and required by cancer cells for growth, proliferation and survival. In clinical studies, GP88 was detected in >80 percent of breast cancer tumors. High levels of GP88 in such tumors are statistically associated with a five-fold increase in the risk of recurrence, compared with patients with low or no GP88 detected in tumors. GP88 blood levels have been shown to be statistically elevated in breast cancer patients with progressive disease, compared with healthy individuals. Concurrent with the development of GP88 diagnostic kits for detecting GP88 in tumor tissue and blood, A&G is pursuing the development of an associated anti-GP88 monoclonal antibody therapeutic.  In pre-clinical xenograft models, the antibody was demonstrated to inhibit tumor growth and promote tumor regression. Toxicology and safety studies demonstrated anti-GP88 is safe and showed no toxicities in either acute or repeat dose studies. Thanks to an SBIR/NCI grant ($2 million), this therapeutic will enter Phase 1 clinical trials in 2018. The two diagnostic products will be used in this study to identify patients for treatment with the anti-GP88 and subsequently for monitoring patients during and post-treatment.

VLP Therapeutics is dedicated to developing innovative medical treatments and transforming traditional vaccines and targeted antibody therapies to address global unmet medical needs. Its vision is to combat 21st century global public health problems through its i-αVLP (inserted alpha VLP) Technology.

Vheda Health is dedicated to humanizing healthcare through technology. The company’s flagship product is a mobile care management platform that facilitates cost savings for payers by automating care plan compliance. The platform engages Medicaid and Medicare members with a smartphone-enabled mobile app focused on creating new communication channels and monitoring real-time compliance. The result is an average $17,175 per member, per year savings and 71 percent decrease in hospital and ER utilization.

The Low Impact Development Design Group, or LIDDG, manufactures and distributes two storm water best management practice (BMP) product lines.

LIDMIX is a media that is designed to treat the heavy metals zinc (Zn), copper (Cu), and lead (Pb), as well as other metals and non-point source runoff stormwater pollutants. The media can be used in existing media-based stormwater treatment devices, such as cartridges and filters, to enhance their performance.

The other product is LIDMAT™, for which LIDMIX™ media is inserted into a geotextile mat that is formed into modules that can be attached to each other to treat sheet flow or attached to a storm drain structure. A biodegradable version of the LIDMAT™ is also available. It can be planted with hyper accumulators, which will enhance the capture of pollutants.

Milestone Sports Ltd. is focused on connecting retailers and brands to consumers through its Wearable Marketing Platform (WMP). The platform collects comprehensive data from a low-cost foot pod that syncs to a mobile device. This rich, real-life data results in meaningful, personal, and valuable direct marketing: the future of retailer and brand loyalty.

vCalc is an online, crowd-sourced calculating encyclopedia (wiki) with over 12,000 free, online calculators. The company’s information comes from engineers, university professors, students from around the world, and anyone else that chooses to contribute. In addition to accessing the database of calculators and formulas, users are also able to create and contribute their own equations for personal or public use.

MIMETAS US develops and markets Organ‐on‐a‐Chip solutions for the pharmaceutical industry. These products serve as an early stage screening model to predict toxic side effects and drug efficacy. MIMETAS US’ core product is OrganoPlate™, a microfluidics‐based culture plate that enables the culturing and screening of a range of organ and tissue models that have a better toxic and efficacy predictive value than currently available approaches. OrganoPlates™ will be developed for liver, heart, kidney, cancer, and lung models. They are compatible with standard robot and readout equipment, making the technology amenable to highthroughput automation. OrganoPlates™ are based on a proprietary microfluidic liquid handling technique called Phaseguides™.

Plant Sensory Systems LLC is a privately held agricultural biotechnology company that develops proprietary plant technologies for sustainable food, feed, fiber, biofuel and bio-based products. PSS has expertise in modifying plant metabolic pathways and selects those pathways with real commercial value to develop into high-value products. The company is located at bwtech@UMBC Research and Technology Park.

Cellphire Inc. develops stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. The company has stabilized and modified platelets into a hemostatic agent that can be stored well beyond the current limit of five days. Platelets cannot be stockpiled and shortages occur because of this extremely short shelf life. These shortages can interrupt the treatment of cancer patients and actively bleeding surgical or trauma patients.

Cellphire’s first platelet stabilization product is Thrombosome®™, an easily rehydrated platelet product in Phase 1 clinical study for use as a potential agent in radiation remediation. The NB work is being funded by the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary of Preparedness and Response in the U.S. Department of Health and Human Services. Cellphire, through use of its own funds and IP, is also developing other applications and has been intrigued by the concept of utilizing stabilized platelets as drug delivery vehicles.

Manta Biofuel is a producer of renewable algal crude oil that is cost-competitive with traditional crude oil. The company employs technological advantages in a three-step process to produce crude oil from algae. The first is growing algae. Manta can convert algae from any source, leaving options open from farming to collecting natural blooms. For the second step, harvesting the algae, Manta uses a proprietary magnetic harvester that efficiently collects and concentrates algae. The company then converts the algae to crude oil through hydrothermal liquefaction (HTL).

Johnny Oysterseed LLC is a venture founded around the farming of the Eastern Oyster (C. virginica). To date, the company has produced/planted approximately 20 million seed oysters in support of commercial food production and ecosystem restoration. Johnny Oysterseed also produces and sells food oysters under its Calvert Crest and Steamboat Landing labels. Ten years of working closely with oysters, government regulations, markets, and industry has given the company deep insight into the challenges currently confronting oyster farmers. This experience, together with engineering expertise, has led Johnny Oysterseed to invent several technical solutions for oyster farming. These solutions have greatly improved the company’s production while reducing labor costs. After realizing these increased efficiencies, Johnny Oysterseed is focusing on manufacturing and marketing its unique technical solutions to the aquaculture industry, with an initial emphasis on the Chesapeake Bay region and the U.S. eastern seaboard.

Bahari Energy has developed the Bahari Energy Wind Tower Technology, which considers integrated design, environmental conscientiousness, and patented technology to make wind energy accessible, efficient, and cost-competitive in diverse settings. The “windcatcher” technology on the roof of the Wind Tower redirects wind to turbines from 360 degrees, taking advantage of wind turbulence. Nozzles accelerate the wind flow and electricity is generated in wind speeds as low as one mile per hour. The Wind Tower is self-contained, and can stand either alone or on top of/beside a structure, allowing for the integration into architectural designs as an enclosed structure. Since the turbines are enclosed within the Wind Tower, they pose no risk to birds and create no unpleasant noise, vibration, or interference with radar and television transmissions.

Itutela develops a digital messaging platform that connects clinicians, families and community resources to improve access and reduce preventable readmissions. Hospital-based clinicians use the app on any device and are matched through a proprietary algorithm to the patient’s care team, whether inside or outside of their network. After two successful clinical intensive care pilots, a $13,000 savings per patient, 27 percent reduction in readmissions and improved access for rural patients was proven. The company provides the secure, HIPAA-compliant platform at no charge to value-based organizations with a patient-centric focus.